Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study
Go back to Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study| Edwards Lifesciences (NYSE: EW) | Delayed: 88.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $88.26 | 52 Week High | $166.87 | |||
| Open | $88.26 | 52 Week Low | $72.20 | |||
| Day High | $88.26 | P/E | 25.66 | |||
| Day Low | $88.26 | EPS | $3.44 | |||
| Volume | 24 | |||||
